U.S., Nov. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07254585) titled 'SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma' on Nov. 18.
Brief Summary: This study is a n open-label, multi-center, phase II study to evaluate the efficacy and safety of SYS6010 combined with Enlonstobart in the recurrent or metastatic head and neck squamous cell carcinoma.
Study Start Date: Dec. 01
Study Type: INTERVENTIONAL
Condition:
Head and Neck Squamous Cell Carcinoma
Intervention:
DRUG: SYS6010 injection
SYS6010will be administrated on a 14-day cycle
DRUG: Enlonstobart injection
Enlonstobart is a recombinant human anti-PD-1 monoclonal antibody
Recruitment Statu...